- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Oct 31, 2024
Emerging Company Profile
IHP: Creating an EpiPen for sickle cell disease
Company aims to keep patients out of hospital with a dual-mechanism rescue treatment to prevent vaso-occlusive crises
BioCentury | May 31, 2024
Distillery Therapeutics
Reversible aptamer and small molecule-based anticoagulant
BioCentury | Feb 21, 2024
Distillery Therapeutics
Engineered bacteria-guided CAR T cells for solid tumors
BioCentury | Dec 7, 2023
Data Byte
FDA approves six NMEs in November
The four cancer therapies among the approvals included the first AKT inhibitor and the first desmoid tumor therapy
BioCentury | Nov 16, 2023
Deals
Nov. 15 Quick Takes: Kite, Arcellx expand CAR T deal
Plus: Gilde closes new €740M fund and updates from RefleXion, NMD, Lenz-Graphite, Cytovale, T-Therapeutics, Vittoria, CorMedix
BioCentury | Jun 21, 2023
Management Tracks
Jonathan Mow named CEO at Veralox
Plus: Ottesen becomes CMO at Adcendo, and updates from Splice Bio, Shape, C4 and more
BioCentury | Feb 24, 2022
Management Tracks
Philip to succeed Marrazzo at Spark
Plus LaCaze joins Mnemo and updates from Sumitomo, Veracyte, Totus and more
BioCentury | Feb 11, 2022
Distillery Therapeutics
An inhibitor of the ALOX12-ACACA interaction for NASH
Items per page:
1 - 10 of 1056